M-Vax autologous haptenized tumor cell vaccine: AVXT will begin in four weeks a 400-patient pivotal trial

By WIR Staff | Aug 3, 1998 | 7:00 AM GMT

Avax Technologies Inc. (AVXT), Kansas City, Mo.

Read the full 74 word article

How to gain access

Continue reading with a
two-week free trial.